Biotech Values

[mskatiescarletohara]

I also think these latest investors who were involved today's placement may have conducted business with Imasogie in a previous pharma/biotech transaction non-affiliated with GENR. Imasogie does have contacts...yes? I also feel Imasogie is implementing some strategy, advising GENR to advance the Phase II study solely without the help of pharma. I think Imasogie feels the value of the compound will further increase negotiating power by conducting such a study without partnering right now, also the placement established GENR is not backed into a corner, and can raise cash on decent terms. This company has accomplished a lot in the last year. Good clinical data talks, and bad clinical data walks.

I also sense "management" is becoming synergistic with each other, by utilizing their individual capacities to execute a gameplan in moving the company forward. GENR has a new CFO, a COO with manufacturing experience, a dealmaker on the BOD affluent with 'big money' and pharma, and a dedicated CEO focused on the science.

With regard to the FDA, the last thing anyone wants is to get into the FDA doghouse, I think the increased cash position sets the stage for a green light on the IND.

katie...